Meeting
2020 ASCO Virtual Scientific Program
Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial.
Authors
Neelima Vidula
Massachusetts General Hospital, San Francisco, CA
Neelima Vidula , Rita Nanda , Kathy Miller , Paula Raffin Pohlmann , Vandana G Abramson , Leisha A. Emens , Ben Ho Park , Minetta C. Liu , Andrei Goga , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT03095352
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS1114)
DOI
10.1200/JCO.2020.38.15_suppl.TPS1114
Abstract #
TPS1114
Poster Bd #
199
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.
First Author: Neelima Vidula
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis.
First Author: Steven Brad Maron
Poster
2018 ASCO Annual Meeting
A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.
First Author: Neelima Vidula
Poster
2016 ASCO Annual Meeting
KEYNOTE-181: phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.
First Author: Toshihiko Doi